Maze Appoints Paula Johnson & Sophie Kornowski to Board
Maze Therapeutics, a clinical-stage biopharmaceutical company, announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. These appointments are made at a crucial time as the company progresses its development programs, with upcoming data readouts for MZE829 and MZE782 in late 2026 and 2027, respectively. Both new board members bring extensive clinical, research, and biopharmaceutical leadership experience to support Maze's mission.
Key Highlights
- Paula Johnson, M.D., M.P.H., appointed to Maze's Board of Directors.
- Sophie Kornowski, Pharm.D., M.B.A., appointed to Maze's Board of Directors.
- Dr. Johnson brings over 30 years of clinical and research experience, including serving on the J&J Board.
- Dr. Kornowski brings over 35 years of biopharmaceutical leadership experience, including as CEO of Boston Pharmaceuticals.
- Maze expects additional data from MZE829 in late 2026 or early 2027.
- Maze expects initial data from MZE782 in 2027.
- Additional trial initiations for both MZE829 and MZE782 are planned for next year.
Price Impact
More from MAZE
Maze Therapeutics Q2 Net Loss $(44.7M); Raises $144.6M Equity, $40M Debt
Maze Therapeutics Q2 Net Loss $44.7M; $495M Cash, Runway into 2029
Maze Therapeutics Reports Q2 Results; Clinical Trials Advance, Cash $495M